Clostridioides difficile Infection in Patients with Chronic Kidney Disease: A Systematic Review

Table 3

Outcome measures.

Outcome	Study	Participants	Results
			Baseline	Posttesting	% change
Cure rate (no. of patients)	Mullane et al. 2013 [32]	Fidaxomycin stage 3 CKD	112	89	79.5
		Fidaxomycin stage 4 CKD	46	34	73.9
		Vancomycin stage 3 CKD	113	91	80.5
		Vancomycin stage 4 CKD	50	38	76.0
	Cammarota et al. 2015 [33]	FMT	20	18	90.0
		Vancomycin	19	12	63.2
	Lackowicz et al. 2014 [30]	Nephrology ward patients	9	4	44.4
	Kujawa et al. 2015 [29]	LP299v	21	19	90.4
Recurrence (no. of patients)	Mullane et al. 2013 [32]	Fidaxomycin stage 3 CKD	89	19	21.4
		Fidaxomycin stage 4 CKD	34	5	14.7
		Vancomycin stage 3 CKD	91	30	33.0
		Vancomycin stage 4 CKD	38	12	31.6
	Lackowicz et al. 2014 [30]	Nephrology ward patients	4	3	75.0
	Cammarota et al. 2015 [33]	FMT	18	2	11.1
		Vancomycin	17	12	70.5
	Kujawa et al. 2015 [29]	LP299v	21	2	9.0
Mortality (no. of patients)	Mullane et al. 2013 [32]	Stage 3 CKD	—	—	—
		Stage 4 CKD	—	—	—
	Lackowicz et al. 2014 [30]	Nephrology ward patients	9	2	22
	Cammarota et al. 2015 [33]	FMT	20	2	10
		Vancomycin	19	6	31.5
Duration of diarrhea (days)	Kujawa et al. 2015 [29]	LP299v in the patients with recurrence ()	28	9.5	33.9
Number of stools per day	Kujawa et al. 2015 [29]	LP299v in the patients with recurrence ()	8	7	—
Average CRP serum concentration (mg/l)	Kujawa et al. 2015 [29]	LP299v in the patients with recurrence ()	96.5	43.8